(Press-News.org) HOUSTON, SAN DIEGO and LONDON ― The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T cell receptor natural killer (TCR NK) cell therapy for advanced synovial sarcoma and myxoid/round cell liposarcoma. MD Anderson is the IND sponsor.
NY-ESO-1 TCR/IL-15 NK is being developed by Syena, an oncology-focused product company launched by Replay and MD Anderson based upon the scientific discoveries of Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation & Cellular Therapy at MD Anderson. Syena has an exclusive licensing agreement for MD Anderson’s TCR NK platform. This first-in-class engineered cell therapy is comprised of cord blood-derived natural killer cells that express an affinity-enhanced T cell receptor (TCR) targeted against the NY-ESO-1 cancer-associated antigen, which is highly immunogenic and expressed on numerous cancer cell types. The ability of NY-ESO-1 to elicit humoral and cellular immune responses, along with its restricted tissue expression, establishes it as a compelling target for cancer immunotherapy.
The Phase I/Ib study will assess the safety and efficacy of NY-ESO-1 TCR/IL-15 NK in patients with synovial sarcoma and myxoid/round cell liposarcoma. It will be administered following lymphodepletion with standard doses of fludarabine/cyclophosphamide (Flu/Cy). Approximately 44 patients will be enrolled into the study, anticipated to commence in Q3 2023.
"Syena is leveraging the scalability and allogeneic nature of engineered cord blood-derived NK cells to democratize cell therapy for cancer treatment. The recent FDA IND clearance of the first-in-human TCR-NK protocol is a significant milestone for Syena," said Adrian Woolfson, executive chairman, president and co-founder of Replay. “Syena is now one step closer to bringing its first-in-class, ‘off-the-shelf’ engineered TCR-NK therapy to patients with solid tumors.”
“Following the FDA IND acceptance, Syena is Replay’s first product company to enter the clinic,” said Lachlan MacKinnon, chief executive officer and co-founder of Replay. “The ability to secure rapid FDA IND clearance for our first-in-class TCR-NK program is a testament to the caliber of our team and quality of our science, and continues to validate our business model.”
“Synovial and myxoid/round cell liposarcomas express NY-ESO-1 at high levels and in a high frequency of cells, making them excellent tumor types for establishing proof of concept for the TCR-NK platform,” said Rezvani. “I am delighted with the team's progress and look forward to initiating the Phase I/Ib study later this year.”
Read the full press release on the MD Anderson newsroom.
- 30 -
Disclosure
MD Anderson has an institutional conflict of interest with Replay and Syena, and MD Anderson will implement an Institutional Conflict of Interest Management and Monitoring Plan to manage these relationships.
About Replay
Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and delivering big DNA. The Company has assembled a toolkit of disruptive platform technologies — including a high payload capacity HSV platform, a hypoimmunogenic cell therapy platform, and a genome writing platform — to address the challenges currently limiting clinical progress and preventing genomic medicine from realizing its potential.
The Company’s hub-and-spoke business model separates technology development within Replay from therapeutic development in a portfolio of product companies that leverage its technology platforms. For example, the Company recently incorporated a first-in-class engineered TCR-NK cell therapy product company using technology developed by Katy Rezvani, M.D., Ph.D., at The University of Texas MD Anderson Cancer Center in Houston, Texas. Replay’s synHSV™ technology, a high payload capacity HSV vector capable of delivering up to 30 times the payload of AAV, is utilized by Replay’s four gene therapy product companies, bringing big DNA treatments to diseases affecting the skin, eye, brain, and muscle. Replay is led by a distinguished team of academics, entrepreneurs, and industry experts.
The Company raised $55 million in seed financing in July 2022 and is supported by an international syndicate of investors including: KKR, OMX Ventures, ARTIS Ventures and Lansdowne Partners.
Replay is headquartered in San Diego, California. For further information please visit www.replay.bio and follow us on LinkedIn and Twitter.
About MD Anderson
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 53 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is No. 1 for cancer in U.S. News & World Report’s “Best Hospitals” rankings and has been named one of the nation’s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).
END
MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for sarcoma
First-in-human Phase I study of NY-ESO-1 TCR/IL-15 NK for advanced synovial sarcoma and myxoid/round cell liposarcoma anticipated to commence Q3 2023
2023-06-20
ELSE PRESS RELEASES FROM THIS DATE:
New study reveals irrigation’s mixed effects around the world
2023-06-20
The analysis, which appears in the journal Nature Reviews Earth and Environment, also points to ways to improve assessments in order to achieve sustainable water use and food production in the future.
“Even though irrigation covers a small fraction of the earth, it has a significant impact on regional climate and environments—and is either already unsustainable, or verging on towards scarcity, in some parts of the world,” explains Sonali Shukla McDermid, an associate professor in NYU’s Department of Environmental Studies and the paper’s lead author. “But because irrigation supplies 40% of the world’s food, we need to understand ...
Open-source software to speed up quantum research
2023-06-20
Quantum technology is expected to fundamentally change many key areas of society. Researchers are convinced that there are many more useful quantum properties and applications to explore than those we know today. A team of researchers at Chalmers University of Technology in Sweden have now developed open-source, freely available software that will pave the way for new discoveries in the field and accelerate quantum research significantly.
Within a few decades, quantum technology is expected to become a key technology in areas such as health, communication, defence and energy. The ...
Fish farms can become biogas producers
2023-06-20
Digesting fish waste can allow circular fish and vegetable farms (aquaponics) to produce biogas that can be fed back into the energy system of these farms. This also generates excellent nutrition for plants, according to new research from the University of Gothenburg.
There is increasing growth in circular, land-based, combined fish and vegetable farms- often referred to as aquaponics. Aquaponics makes use of nutrient-rich water produced by fish (aquaculture) which can be used to fertilise plants (hydroponics) ...
Machine learning helps researchers identify hit songs with 97% accuracy
2023-06-20
Every day, tens of thousands of songs are released. This constant stream of options makes it difficult for streaming services and radio stations to choose which songs to add to playlists. To find the ones that will resonate with a large audience, these services have used human listeners and artificial intelligence. This approach, however, lingering at a 50% accuracy rate, does not reliably predict if songs will become hits.
Now, researchers in the US have used a comprehensive machine learning technique applied to brain responses and were able to predict ...
Completing genome of rusty patched bumble bee may offer new approach to saving endangered bee
2023-06-20
LOGAN, Utah, June 20, 2023 — A detailed, high-resolution map of the rusty patched bumble bee’s genome has been released by U.S. Department of Agriculture (USDA) Agricultural Research Service (ARS) and U.S. Fish and Wildlife Service (USFWS) scientists, offering new possible approaches for bringing the native pollinator back from the danger of extinction.
Putting together the rusty patched bumble bee genome is part of the Beenome 100 project, a first-of-its-kind effort to create a library of high-quality, ...
Face of Anglo-Saxon teen VIP revealed with new evidence about her life
2023-06-20
The face of a 16-year-old woman buried near Cambridge (UK) in the 7th century with an incredibly rare gold and garnet cross (the ‘Trumpington Cross’) has been reconstructed following analysis of her skull. The striking image is going on public display for the first time on 21st June, with new scientific evidence showing that she moved to England from Central Europe as a young girl, leading to an intriguing change in her diet.
The image and artefacts from the mysterious woman’s ...
Weak policies and political ideologies risk jeopardizing plans to tackle health and climate change, says Cambridge expert
2023-06-20
Weak policies and political ideologies risk jeopardising plans to tackle health and climate change, says Cambridge expert
Efforts to tackle major issues facing the UK, including the nation’s health and climate change, are being hampered because politicians often ignore the existing evidence when setting policies, according to Dame Theresa Marteau, a public health expert at the University of Cambridge.
Writing in the journal Science and Public Policy, Professor Marteau argues that this ‘evidence-neglect’ is a result of incentive structures that encourage politicians to set ambitious policy goals while simultaneously disincentivising ...
Low-dose aspirin use associated with 20% increased anemia risk in older adults
2023-06-19
1. Low-dose aspirin use associated with 20% increased anemia risk in older adults
Abstract: https://www.acpjournals.org/doi/10.7326/M23-0675
URL goes live when the embargo lifts
An analysis of the ASPREE (ASPirin in Reducing Events in the Elderly) trial found that the use of low-dose aspirin was associated with a 20 percent increased incidence of anemia and decline in ferritin, or blood iron levels, in otherwise healthy older adults. These findings suggest that periodic monitoring of hemoglobin should be considered in older patients taking aspirin. The analysis is published in Annals ...
Chinese paleogeneticist FU Qiaomei awarded UNESCO–AI Fozan International Prize for the Promotion of Young Scientists
2023-06-19
FU Qiaomei, a paleogeneticist at the Chinese Academy of Sciences (CAS), received the UNESCO–AI Fozan International Prize for the Promotion of Young Scientists in Science, Technology, Engineering and Mathematics (STEM) on June 19 in Paris, France, for her “seminal work on the history of early humans in Eurasia, based on genetic lineage studies, which provides new insights on the early human history of Eurasia and perspectives on the evolution of human health.”
She was one of five young scientists from around the world to receive the prize, alongside researchers from Argentina, Cameroon, Egypt, and Serbia. The laureates were ...
Clean, sustainable fuels made ‘from thin air’ and plastic waste
2023-06-19
Researchers have demonstrated how carbon dioxide can be captured from industrial processes – or even directly from the air – and transformed into clean, sustainable fuels using just the energy from the Sun.
The researchers, from the University of Cambridge, developed a solar-powered reactor that converts captured CO2 and plastic waste into sustainable fuels and other valuable chemical products. In tests, CO2 was converted into syngas, a key building block for sustainable liquid fuels, and plastic bottles were converted into glycolic acid, which is widely used in the cosmetics industry.
Unlike earlier tests ...
LAST 30 PRESS RELEASES:
New route to ‘quantum spin liquid’ materials discovered for first time
Chang’e-6 basalts offer insights on lunar farside volcanism
Chang’e-6 lunar samples reveal 2.83-billion-year-old basalt with depleted mantle source
Zinc deficiency promotes Acinetobacter lung infection: study
How optogenetics can put the brakes on epilepsy seizures
Children exposed to antiseizure meds during pregnancy face neurodevelopmental risks, Drexel study finds
Adding immunotherapy to neoadjuvant chemoradiation may improve outcomes in esophageal cancer
Scientists transform blood into regenerative materials, paving the way for personalized, blood-based, 3D-printed implants
Maarja Öpik to take up the position of New Phytologist Editor-in-Chief from January 2025
Mountain lions coexist with outdoor recreationists by taking the night shift
Students who use dating apps take more risks with their sexual health
Breakthrough idea for CCU technology commercialization from 'carbon cycle of the earth'
Keck Hospital of USC earns an ‘A’ Hospital Safety Grade from The Leapfrog Group
Depression research pioneer Dr. Philip Gold maps disease's full-body impact
Rapid growth of global wildland-urban interface associated with wildfire risk, study shows
Generation of rat offspring from ovarian oocytes by Cross-species transplantation
Duke-NUS scientists develop novel plug-and-play test to evaluate T cell immunotherapy effectiveness
Compound metalens achieves distortion-free imaging with wide field of view
Age on the molecular level: showing changes through proteins
Label distribution similarity-based noise correction for crowdsourcing
The Lancet: Without immediate action nearly 260 million people in the USA predicted to have overweight or obesity by 2050
Diabetes medication may be effective in helping people drink less alcohol
US over 40s could live extra 5 years if they were all as active as top 25% of population
Limit hospital emissions by using short AI prompts - study
UT Health San Antonio ranks at the top 5% globally among universities for clinical medicine research
Fayetteville police positive about partnership with social workers
Optical biosensor rapidly detects monkeypox virus
New drug targets for Alzheimer’s identified from cerebrospinal fluid
Neuro-oncology experts reveal how to use AI to improve brain cancer diagnosis, monitoring, treatment
Argonne to explore novel ways to fight cancer and transform vaccine discovery with over $21 million from ARPA-H
[Press-News.org] MD Anderson and Replay announce FDA clearance of IND application for first-in-class TCR NK cell therapy for sarcomaFirst-in-human Phase I study of NY-ESO-1 TCR/IL-15 NK for advanced synovial sarcoma and myxoid/round cell liposarcoma anticipated to commence Q3 2023